Valeur202020212022202320242025Total du passif105.73 M120.33 M177.74 M140.92 M80 M62.17 MTotal des capitaux propres44.42 M91.17 M60.43 M18.86 M56.39 M92.25 MTotal du passif et des capitaux propres150.16 M211.5 M238.17 M159.78 M136.39 M154.42 MDette totale——————Dette nette——————
Precision BioSciences, Inc. - Common Stock
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.